These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 25384074)

  • 41. [Motor association cortex activity in Parkinson's disease--a functional MRI study].
    Tada Y
    Rinsho Shinkeigaku; 1998 Aug; 38(8):729-35. PubMed ID: 9916518
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effect of levodopa on both verbal and motor representations of action in Parkinson's disease: a fMRI study.
    Péran P; Nemmi F; Méligne D; Cardebat D; Peppe A; Rascol O; Caltagirone C; Demonet JF; Sabatini U
    Brain Lang; 2013 Jun; 125(3):324-9. PubMed ID: 22841350
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Parkinson's disease duration determines effect of dopaminergic therapy on ventral striatum function.
    MacDonald AA; Monchi O; Seergobin KN; Ganjavi H; Tamjeedi R; MacDonald PA
    Mov Disord; 2013 Feb; 28(2):153-60. PubMed ID: 23165957
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A placebo-controlled evaluation of ropinirole, a novel D2 agonist, as sole dopaminergic therapy in Parkinson's disease.
    Brooks DJ; Abbott RJ; Lees AJ; Martignoni E; Philcox DV; Rascol O; Roos RA; Sagar HJ
    Clin Neuropharmacol; 1998; 21(2):101-7. PubMed ID: 9579296
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Successful treatment of post-stroke apathy by the dopamine receptor agonist ropinirole.
    Kohno N; Abe S; Toyoda G; Oguro H; Bokura H; Yamaguchi S
    J Clin Neurosci; 2010 Jun; 17(6):804-6. PubMed ID: 20378354
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Use of magnetic resonance imaging in pharmacogenomics.
    Viviani R; Lehmann ML; Stingl JC
    Br J Clin Pharmacol; 2014 Apr; 77(4):684-94. PubMed ID: 23802603
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Distinct functional and macrostructural brain changes in Parkinson's disease and multiple system atrophy.
    Planetta PJ; Kurani AS; Shukla P; Prodoehl J; Corcos DM; Comella CL; McFarland NR; Okun MS; Vaillancourt DE
    Hum Brain Mapp; 2015 Mar; 36(3):1165-79. PubMed ID: 25413603
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Sex differences in the pharmacokinetics of levodopa in elderly patients with Parkinson disease.
    Kumagai T; Nagayama H; Ota T; Nishiyama Y; Mishina M; Ueda M
    Clin Neuropharmacol; 2014; 37(6):173-6. PubMed ID: 25384078
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pramipexole extended-release: a review of its use in patients with Parkinson's disease.
    Frampton JE
    Drugs; 2014 Dec; 74(18):2175-90. PubMed ID: 25385556
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Medications for Parkinson's disease.
    Hoffmann RP
    P T; 2014 Nov; 39(11):759. PubMed ID: 25395818
    [No Abstract]   [Full Text] [Related]  

  • 51. Dopaminergic basis for impairments in functional connectivity across subdivisions of the striatum in Parkinson's disease.
    Bell PT; Gilat M; O'Callaghan C; Copland DA; Frank MJ; Lewis SJ; Shine JM
    Hum Brain Mapp; 2015 Apr; 36(4):1278-91. PubMed ID: 25425542
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A network centred on the inferior frontal cortex is critically involved in levodopa-induced dyskinesias.
    Cerasa A; Koch G; Donzuso G; Mangone G; Morelli M; Brusa L; Stampanoni Bassi M; Ponzo V; Picazio S; Passamonti L; Salsone M; Augimeri A; Caltagirone C; Quattrone A
    Brain; 2015 Feb; 138(Pt 2):414-27. PubMed ID: 25414038
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Combined rasagiline and antidepressant use in Parkinson disease in the ADAGIO study: effects on nonmotor symptoms and tolerability.
    Smith KM; Eyal E; Weintraub D;
    JAMA Neurol; 2015 Jan; 72(1):88-95. PubMed ID: 25420207
    [TBL] [Abstract][Full Text] [Related]  

  • 54. PERFORM: a system for monitoring, assessment and management of patients with Parkinson's disease.
    Tzallas AT; Tsipouras MG; Rigas G; Tsalikakis DG; Karvounis EC; Chondrogiorgi M; Psomadellis F; Cancela J; Pastorino M; Waldmeyer MT; Konitsiotis S; Fotiadis DI
    Sensors (Basel); 2014 Nov; 14(11):21329-57. PubMed ID: 25393786
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The relationship between obsessive-compulsive symptoms and PARKIN genotype: The CORE-PD study.
    Sharp ME; Caccappolo E; Mejia-Santana H; Tang MX; Rosado L; Orbe Reilly M; Ruiz D; Louis ED; Comella C; Nance M; Bressman S; Scott WK; Tanner C; Waters C; Fahn S; Cote L; Ford B; Rezak M; Novak K; Friedman JH; Pfeiffer R; Payami H; Molho E; Factor SA; Nutt J; Serrano C; Arroyo M; Pauciulo MW; Nichols WC; Clark LN; Alcalay RN; Marder KS
    Mov Disord; 2015 Feb; 30(2):278-83. PubMed ID: 25393808
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The Next Step: A Common Neural Mechanism for Freezing of Gait.
    Lewis SJ; Shine JM
    Neuroscientist; 2016 Feb; 22(1):72-82. PubMed ID: 25398230
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical correlations with Lewy body pathology in LRRK2-related Parkinson disease.
    Kalia LV; Lang AE; Hazrati LN; Fujioka S; Wszolek ZK; Dickson DW; Ross OA; Van Deerlin VM; Trojanowski JQ; Hurtig HI; Alcalay RN; Marder KS; Clark LN; Gaig C; Tolosa E; Ruiz-Martínez J; Marti-Masso JF; Ferrer I; López de Munain A; Goldman SM; Schüle B; Langston JW; Aasly JO; Giordana MT; Bonifati V; Puschmann A; Canesi M; Pezzoli G; Maues De Paula A; Hasegawa K; Duyckaerts C; Brice A; Stoessl AJ; Marras C
    JAMA Neurol; 2015 Jan; 72(1):100-5. PubMed ID: 25401511
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Identification of potential drugs for Parkinson's disease based on a sub-pathway method.
    Sun AG; Lin AQ; Huang SY; Huo D; Cong CH
    Int J Neurosci; 2016; 126(4):318-25. PubMed ID: 25405535
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A rat model of striatonigral degeneration generated by simultaneous injection of 6-hydroxydopamine into the medial forebrain bundle and quinolinic acid into the striatum.
    Yoon HH; Kim YH; Shin ES; Jeon SR
    J Korean Med Sci; 2014 Nov; 29(11):1555-61. PubMed ID: 25408589
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pharmacological profile of opicapone, a third-generation nitrocatechol catechol-O-methyl transferase inhibitor, in the rat.
    Bonifácio MJ; Torrão L; Loureiro AI; Palma PN; Wright LC; Soares-da-Silva P
    Br J Pharmacol; 2015 Apr; 172(7):1739-52. PubMed ID: 25409768
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.